Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

RA Patients May Be Less Likely to Discontinue Etanercept Than Other TNF Inhibitors

  |  

The authors identified only 25 papers that reported drug survival rates at 48 months and noted these papers reported a wide range of survival. In the first-line setting, survival rates ranged from 3–95% for etanercept, 4–100% for adalimumab and 18–79% for infliximab. When the investigators performed an exploratory analysis of TNF inhibitor survival rates in patients receiving etanercept, adalimumab and infliximab monotherapy, they found etanercept had the highest survival rate at each evaluated time point.

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Emery P, Vlahos B, Szczypa P, et al. Long-term drug survival of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol. 2019 Jun 1. pii: jrheum.181398. [Epub ahead of print]

Related Articles

    Remembering Etanercept & the Advent of the Biologic Era

    As a veteran rheumatologist, I remember the clinical trials of etanercept’s (Enbrel’s) efficacy. And when the drug was first approved in 1998, I participated in those clinical trials and realized the effectiveness was astonishing. It was easy to tell which patients were treated with etanercept vs. those who received placebo, even though both groups were…

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    Andrew Brookes / Image Source on Offset

    Clinical Insights into Axial Spondyloarthritis: Rheumatology Drugs at a Glance, Part 5

    Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…